Clinical Trial Update: BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment [Phase 2]

View source ↗

Summary

An update on a Phase 2 clinical trial evaluating BBR 3464 in patients with metastatic small cell lung cancer that has not responded to prior treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• BBR 3464

Snippet

Sponsor: Theradex | Conditions: Lung Cancer | Phase 2 | Status: UNKNOWN